期刊文献+

高血压病血瘀证患者血清对血管内皮细胞分泌vWF、TM、EPCR的影响及丹参酮Ⅱ_A的干预作用 被引量:8

Effect of Tanshinone Ⅱ_A on vWF,TM and EPCR from patients with hypertension plus blood stasis
下载PDF
导出
摘要 目的:探讨高血压病血瘀证患者血清对血管内皮细胞分泌vWF、TM、EPCR的影响及丹参酮ⅡA的干预作用。方法:将培养的人脐静脉内皮细胞株CRL-1730按照不同的作用血清,分为血瘀组、非血瘀组、健康组及对照组,作用时间为24 h;药物的作用分组分为血瘀组及丹参酮ⅡA40、20、10、5μg/mL组,药物组为血瘀证患者血清和药物同时加入细胞内培养,作用时间为24 h,采用ELISA法测定细胞培养上清液的vWF、TM、EPCR。结果:血瘀组、非血瘀组、健康组分泌的vWF、TM、EPCR与对照组比较,分泌量较大;血瘀组、非血瘀组分泌的vWF、TM、EPCR与健康组比较,分泌量较大,其中,血瘀组与健康组比较,差异显著(P<0.05或P<0.01);丹参酮ⅡA的某些浓度可以减少血瘀组细胞分泌的vWF、TM、EPCR,其分泌量与血瘀组比较,差异显著(P<0.05或P<0.01)。结论:高血压病血瘀证患者血清可以促进CRL-1730分泌vWF、TM、EPCR,丹参酮ⅡA的某些浓度可以减少血瘀证患者血清作用后细胞分泌的vWF、TM、EPCR。 AIM: To research the effect of serum from patients with blood stasis syndrome(BSS) associated with hypertension disease on vWF、TM、EPCR excreted by ECV-304 and Tanshinone ⅡA s intervention. METHODS: Cultivated human umbilical vein endothelial cells(CRL-1730) were divided into four groups,according to different serum of patients with BSS associated with hypertension disease,BSS(model) group,non-blood stasis group,health group and control group.The incubation time was 24 h.Tanshinone ⅡA was of different concentrations ( 40 .20 ,10 .5 μg/mL) , all Tanshinone IIA groups' cells were incubated by patients' serum and Tanshinone IIA for 24 h. vWF, TM and EPCR were assayed by enzyme-linked immunosorbent assay (ELISA). RESULTS: vWF, TM and EPCR secreted were higher in the model group, the nonblood stasis group and the health group than those in the control group; vWF, TM and EPCR secreted were higher in the model group, the nonblood sta- sis group than those in the health group; Thereinto, the difference was distinct between the model group and the health group( P 〈0.05 or P 〈0.01 ) ; Tanshinone IIA concentrations can decrease in the amount of vWF, TM and EPCR secreted by the model ceils, there was distinct difference between the Tanshinone ⅡA group and the model group (P 〈 0.05 or P 〈 0.01 ). CONCLUSION : Patients' serum can increase in the amount of vWF, TM and EPCR secreted by the model cells, Tanshinone ⅡA concentrations can decrease in the amount of vWF, TM and EPCR.
出处 《中成药》 CAS CSCD 北大核心 2009年第9期1322-1325,共4页 Chinese Traditional Patent Medicine
基金 国家自然科学基金项目(30572289) 广东省自然科学基金项目(5006019)
关键词 高血压病 血瘀证 人脐静脉内皮细胞 酶联免疫 丹参酮ⅡA hypertension disease blood stasis syndrome ECV-304 ELISA Tanshinone Ⅱ_A
  • 相关文献

参考文献7

二级参考文献35

共引文献35

同被引文献112

引证文献8

二级引证文献89

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部